ASS1 and neoplasm: PEGylated arginine deiminase (ADI-PEG 20) has been applied to clinical anti-tumor therapy of HCC, melanoma and other ASS1-deficient cancers by depleting the external supply of arginine (108), which has also been shown to affect the hypoxia-induced processes by inhibiting HIF signal (109).